Fate Of COVID-19 Convalescent Plasma Clinical Trials At Stake As US FDA Weighs EUA
Executive Summary
Clinical trials would have to move outside US if agency issues emergency use authorization for convalescent plasma, NYU prof says; experts disagree on whether the FDA should issue EUA.
You may also be interested in...
Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
Warp Speed’s Woodcock Encourages Institutions To Continue COVID-19 Plasma Controlled Trial
Seeking to prevent negative fallout from emergency use authorization, Woodcock and NIH Director Collins ask investigators to prioritize a controlled trial of convalescent plasma currently underway in outpatients.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: